Frontlight ResearchEarly access
Taking people in HungaryPhase 4
Immune system changes in brain cancer patients receiving bevacizumab infusion
Tests how bevacizumab infusion affects the immune system in adults with glioblastoma, a brain cancer.
Key facts
- Who runs it
- Orszagos Onkologiai Intezet
- Where
- Budapest XII and Szeged, HungarySee the 2 sites
- Registry title
- Brain cancer and changes in immune system
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 175 people, planned
- Started
- 28 Jun 2024
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 28 June 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with glioblastoma multiforme (a brain cancer) who are treated with bevacizumab. It studies changes in the immune system.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Glioblastoma multiforme that has not come back (before radiotherapy and temozolomide), or that has come back after other treatment.
- Earlier treatment
- People whose cancer came back must already have had other treatment (surgery, radiotherapy and temozolomide). Some people already receiving bevacizumab for a relapse can also join.
Main reasons for not taking part
- Hypersensitivity to bevacizumab or its excipients, or to CHO cell products or other recombinant human or humanised antibodies
- History of psychiatric diseases and treatment
- Another cancer besides glioblastoma multiforme
- Took part in another clinical trial within the last 3 months
- Known drug or chronic alcohol abuse
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Not recurrent glioblastoma multiforme patients (either after opus or with no opus) before radiotherapy and temozolomide therapy. Recurrent patients who have already undergone other therapeutic intervention (surgery, radiotherapy and temozolomide therapy) and due to the recurrence of the disease, based on clinical experience, it is justified to start bevacizumab therapy. Known relapse patients who are already receiving bevacizumab therapy
Who cannot take part
- Unwillingness to sign the written Informed Consent Form. History of psychiatric diseases and treatment. Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies. Participation in another clinical trial within 3 months prior to this study. Known drug or chronic alcohol abuse, drug addiction. Malignant disease other than GBM. Legal incapacity and/or other circumstances rendering the subject unable to understand the nature, scope and possible consequences of the study. Evidence of an uncooperative attitude. Vulnerable subject
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old are you?
Where in Hungary
- Orszagos Onkologiai IntezetBudapest XII, HungaryTaking people
- University of SzegedSzeged, HungaryTaking people
About the trial
What the trial wants to find out
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
- Plain-language title
- Immune system changes in brain cancer patients receiving bevacizumab infusionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-512136-30-00, who can take part
- Record updated
- 28 June 2024